Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA.
Blood Cancer J. 2019 Mar 5;9(3):30. doi: 10.1038/s41408-019-0193-9.
The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.
淀粉样变是一组具有重叠临床表现的疾病,其特征为错误折叠的蛋白质聚集和组织沉积。淀粉样蛋白形成蛋白的性质和来源决定了治疗方法,因此正确的亚型分类对患者的管理至关重要。我们报告了通过液相色谱-串联质谱联用技术确诊的 9 例两种淀粉样蛋白类型的临床病理特征。最常见的类型是转甲状腺素蛋白(n=9)和免疫球蛋白衍生的(n=7)。尽管存在单克隆丙种球蛋白病,但有 2 例患者没有免疫球蛋白衍生的淀粉样变性。8 例患者同时诊断出两种类型,1 例患者的诊断间隔为 11 年。淀粉样蛋白的组织病理学分布具有变异性,可见血管、间质和骨膜沉积。在 7 例患者中发现第二种类型是偶然的,但在 1 例患者中导致了遗传咨询,在另 1 例患者中则针对两种淀粉样蛋白亚型进行了治疗。由于多发性骨髓瘤和 AL 淀粉样变性患者的生存率延长,以及由于人口老龄化导致野生型转甲状腺素蛋白淀粉样变性患者的患病率增加,在单个患者中出现两种淀粉样蛋白类型的现象将更为常见。鉴于针对转甲状腺素蛋白淀粉样变性的革命性新疗法(patisiran、tafamidis 和 inotersen),识别双重淀粉样蛋白类型具有重要的临床意义。